Vanda Pharmaceuticals Inc.
VNDAHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeVanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. With a market capitalization of $242.5M, it sits in micro-cap territory. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Market Cap
$242.5M
Beta
0.69
P/E (TTM)
—
P/E (Fwd)
20.05
EPS (TTM)
$-4.63
EPS (Fwd)
$0.20
ROE
-77.8%
ROA
-22.4%
Cash
$170.0M
Total Debt
$22.8M
Free CF
-$86.7M
52W Change
-28.5%
Annual Financials
Cash vs Debt
Where VNDA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, VNDA finished 30.91% below its 150-day moving average ($5.92) and 35.89% below its 200-day moving average ($6.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VNDA overbought or oversold?
At the October 20, 2026 close, VNDA's RSI(14) was 12.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $170.0M in cash and $22.8M in debt, VNDA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$86.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -77.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $254.4M to $216.1M.
The relatively low beta of 0.69 suggests VNDA is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, VNDA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing VNDA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.